Shots:
- Ethris presented full topline data from P-I trial of ETH47 (nasal) in 40 healthy subjects as a potential treatment for uncontrollable asthma
- Study showed dose-dependent IFNλ production in nasal lining fluid above therapeutic levels & activated antiviral ISG mRNA expression in nasal brush samples, confirming ETH47’s pharmacodynamic activity & MoA. Based on this, Ethris filed a CTA to initiate a P-IIa trial for asthma pts in Q2’25 to assess its efficacy in reducing lower respiratory symptoms incl. rhinovirus
- ETH47 (mRNA) nasal spray developed by using Ethris’ SNIM RNA & SNaP LNP platform, triggers a local cascade of antiviral interferon-stimulated genes and provide relief in asthmatic symptoms
Ref: Businesswire | Image: Ethris
Related News:- Roche Reports Topline Data from P-III (INAVO120) Trial of Itovebi (Inavolisib) to Treat HR-Positive Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
